• Haldun Kar, Sultan Deniz Altındağ, Demet Etit, Seyran Yiğit, Nihan Acar, Mustafa Agah Tekindal, Özlem Gür, Betül Küçükzeybek, Özgün Akgül, and Kemal Atahan.
• Department of General Surgery, Katip Çelebi University Atatürk Training and Research Hospital, İzmir, Turkey.
• Turk J Med Sci. 2021 Dec 13; 51 (6): 299430002994-3000.

Background/AimPaget’s disease (PD) of the breast is a very rare presentation of breast malignancy, accounting for 1%–3% of all primary breast tumors. We aimed to evaluate and compare the clinicopathological features and clinical outcome of PD accompanied by in situ carcinoma and invasive cancer.Materials And MethodsWe used the archive of our pathology laboratory retrospectively for age, sex, history of surgery, histopathological findings, treatment modalities, and follow-up information. We used the Kaplan–Meier method for survival analysis.ResultsThere were 46 female patients diagnosed with PD. In 39 (84.7%) patients, invasive carcinoma accompanied PD, while 7 (15.3%) patients had ductal carcinoma in situ. The median age at diagnosis was 53.5 years. The median follow-up period was 47 months. Of the 39 invasive carcinoma, 10 (25.6%) died during the follow-up period. Invasive ductal carcinoma group had a mean overall survival of rate of 57.8 ± 6.6 months. According to univariate analysis, only the tumor type was found to impact overall survival (p < 0.001).ConclusionsThe current study displayed the tumor type as the only parameter affecting overall survival in the invasive carcinoma group. Although it was not statistically significant, breast cancers accompanied by PD were found to be predominantly advanced stage tumors, high grade, hormone receptor negative, and HER2 positive.This work is licensed under a Creative Commons Attribution 4.0 International License.

27 keywords...

hide…